Over the past few months, the CURED community has been abuzz with eager and excited conversations. Within the walls of our company, the efficacy of our Hemp-Infused, Max Strength Salve is old news; however, as our cannabidiol collective has grown, the daily habit of slathering on our salve is peaking among our partners. Why? Well, that’s simple: because, like all of our products, it works.
Topical CBD is an answer for acute and chronic pain relief. The only guaranteed way to understand the benefits is to try our blissful balm for yourself. But for those of you who love to marry sound science with personal anecdotes, we have you covered.
Chronic Pain Requires Relief
Treating chronic pain is challenging. If you struggle with any variety of daily aches and pains, then you’re familiar with the difficulty of finding a practical and powerful protocol. Oftentimes, it takes multiple rounds of trial and error with pain medications to find a combination that takes the edge off. As if that isn’t enough, patients then need to factor in side effects.
They may find themselves asking if the benefits outweigh the consequences. Unfortunately, this leaves many individuals swapping out one grievance for another.
At CURED, we believe everyone deserves to rise to their full potential, feel their best, and actualize their most passionate pursuits. “Settling” isn’t in our vocabulary, and it shouldn’t be in yours, either. Yet, putting up with a slew of side effects is the equivalent of settling within the realm of our health and wellness.
Chronic pain is insufferable; and if it’s your daily reality, then chronic relief should be a non-negotiable aspect of your life, too. Ingestible CBD, like our Raw, Full-Spectrum Caps, is undeniably efficacious, but there are times when a topical remedy is preferred. Many of the sage seniors in our community rely on topical CBD, and they’re wise to do so.
Treating with Topical CBD
In a four-week, randomized and placebo-controlled trial, twenty-nine patients with symptomatic peripheral neuropathy were studied. Fifteen of these patients were given a product containing 250 mg of CBD, and the remaining fourteen patients were placed into the placebo group. Throughout the trial, patients were given the Neuropathic Pain Scale (NPS) to gauge efficacy of the treatment. The results showed a “significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group.”
The best part? There weren’t any negative side effects. It’s worth repeating: patients experienced significant relief with zero adverse events.
An animal model examining the effectiveness of transdermal (or, topical) CBD for the reduction of inflammation and pain found equally impressive results. A CBD gel was applied over the course of four consecutive days. By the end of this treatment, the gel had “significantly reduced joint swelling, limb posture scores as a rating of spontaneous pain, immune cell infiltration and thickening of the synovial membrane in a dose-dependent manner.”
According to the researchers, the topical application of CBD provided more constant plasma levels of cannabidiol (which produced steadier pain relief) than gastrointestinal administration. Once again, this was accomplished without any reported side effects.
Like we said, we aren’t surprised with the love our Extra-Strength Salve has been receiving in recent weeks. It’s about time it had its moment in the spotlight, and according to the research: the spotlight is well-deserved and here to stay.
What aches and pains do you treat with topical CBD? Reach out, we’d love to hear your story!
Hammell, D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., & Westlund, K. N. (2016). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European journal of pain (London, England), 20(6), 936–948. https://doi.org/10.1002/ejp.818
Xu H. Dixon , Cullen D. Benjamin *, Tang Meng and Fang Yujiang , The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities, Current Pharmaceutical Biotechnology 2020; 21(5). https://dx.doi.org/10.2174/1389201020666191202111534